Skip Navigation

Phase II Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligometastatic Non-Small Cell Lung Cancer and Renal Cell Carcinoma

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05846646

Study #:
STUDY00150529

Start Date:
Nov 15, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05846646

View Complete Trial Details & Eligibility at ClinicalTrials.gov